Φορτώνει......

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

BACKGROUND: Immune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. However, in patients with immunologically “cold” tumors, tumor-resident innate immune cell activation may be required to prime an adaptive immune response and so exploit the full pot...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:	J Immunother Cancer
Κύριοι συγγραφείς:	Mullins, Stefanie R., Vasilakos, John P., Deschler, Katharina, Grigsby, Iwen, Gillis, Pete, John, Julius, Elder, Matthew J., Swales, John, Timosenko, Elina, Cooper, Zachary, Dovedi, Simon J., Leishman, Andrew J., Luheshi, Nadia, Elvecrog, James, Tilahun, Ashenafi, Goodwin, Richard, Herbst, Ronald, Tomai, Mark A., Wilkinson, Robert W.
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BioMed Central 2019
Θέματα:	Research Article
Διαθέσιμο Online:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6739946/ https://ncbi.nlm.nih.gov/pubmed/31511088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0724-8
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Παρόμοια τεκμήρια